INDIA'S INVESTING & TRADING TOOLS RESEARCH LIBRARYPublisher relationship disclosed in our editorial policy
Reviews / Chartink

Chartink Review (2026): Features, Pricing, Pros & Cons

Best for: Intraday technical scanning. Reference pricing: ₹780/month; ₹8,500/year. Free access: Yes.

What is Chartink and who is it best for?

A technical scan builder used for discovering indicator, price and volume conditions in Indian securities. Active technical and swing traders screening for price-action setups. As with every investing research tool, your choice should depend on the questions you ask, how often you need refreshed information and whether you can verify results against primary disclosures. We describe documented capabilities rather than claiming to have run an independent latency or investment-performance test.

What are the main features of Chartink?

  • Flexible scanner-condition builder
  • Breakout, volume and moving-average scans
  • Realtime premium data and scanner intervals
  • Alerts through web, email, SMS and more
  • Dashboards and community scanning ideas

The most useful feature is the one that fits the actual process you follow. Evaluate the available filters, the datasets they operate on, how they handle saved research and whether the interface helps you confirm a screening result. Features advertised on a product page can change across plans or during promotional periods. Check the linked vendor documentation for current entitlements before purchasing.

How much does Chartink cost in 2026?

Reference pricing: ₹780/month; ₹8,500/year. Free access: Yes. Prices or promotions can change. For the current offering and any taxes or add-on exchange data costs, review the official source. Do not choose a platform solely because its subscription price is lower. Compare the features you actually use and whether a free account already solves the research problem.

What are Chartink's advantages and disadvantages?

Advantages

  • Strong technical condition flexibility
  • Supports frequent premium monitoring
  • Transparent public subscription tiers

Limitations

  • Custom conditions take practice
  • Does not replace financial due diligence

Who should not choose Chartink?

If your primary interest is balance-sheet quality and valuation, Screener.in or Finology Ticker may fit better. If your research is infrequent, begin with a free plan before assuming that a paid package will improve your decisions. A screener shows rule matches rather than validated investment opportunities, and any company on a shortlist still requires independent review of financial statements, disclosures, valuation and risks.

Is Chartink worth using in 2026?

Chartink is worth considering if your workflow specifically needs intraday technical scanning. Its approach is custom scans, technical indicators, premium minute-based alerts. The key limitation to understand is: Less focused on company financial research. Explore the full stock screener ranking or compare competing tools before deciding whether to subscribe.

FAQs about Chartink

Does Chartink offer free access?

Yes is the published availability of free access in our comparison. Confirm current sign-up access and limits on the vendor website. Some products limit exports, data intervals, alerts or advanced analysis by tier.

Is Chartink a stock recommendation service?

This profile evaluates screening and research capabilities, not the suitability of any security for a specific investor. Research scores, scans and generated explanations do not guarantee performance. Consider the product documentation and use appropriate financial advice when required.

What is a good alternative to Chartink?

A good alternative depends on your use case: Bullrun for guided Indian stock research, Screener.in for fundamental query flexibility, Chartink for custom technical scans, and TradingView for advanced charts. Different tools can be complementary rather than direct replacements.

Primary source: Chartink product information. All prices and features are subject to change.

Educational tool analysis only. No investment advice. Our publisher is associated with Bullrun; see our disclosure.